| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Identification of differentially expressed genes in oral squamous cell carcinoma.
|
Mol Carcinog
|
2005
|
1.36
|
|
2
|
Expression analysis of E-cadherin, Slug and GSK3beta in invasive ductal carcinoma of breast.
|
BMC Cancer
|
2009
|
1.29
|
|
3
|
Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
|
Life Sci
|
2007
|
1.20
|
|
4
|
Curcumin down regulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells.
|
Toxicology
|
2006
|
1.18
|
|
5
|
Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients.
|
Life Sci
|
2007
|
1.17
|
|
6
|
Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma.
|
Head Neck Oncol
|
2009
|
1.16
|
|
7
|
Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1.
|
Cancer Res
|
2008
|
1.14
|
|
8
|
Over-expression of 14-3-3zeta is an early event in oral cancer.
|
BMC Cancer
|
2007
|
1.09
|
|
9
|
MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma.
|
Oncology
|
2005
|
1.07
|
|
10
|
Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer.
|
Breast Cancer Res Treat
|
2006
|
1.06
|
|
11
|
Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between beta-catenin, dishevelled and cyclin D1 expression.
|
Oncology
|
2008
|
1.06
|
|
12
|
Nuclear S100A7 is associated with poor prognosis in head and neck cancer.
|
PLoS One
|
2010
|
1.04
|
|
13
|
Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
|
Life Sci
|
2010
|
1.04
|
|
14
|
Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma.
|
Int J Cancer
|
2009
|
1.03
|
|
15
|
Epigenetic alterations of CDH1 and APC genes: relationship with activation of Wnt/beta-catenin pathway in invasive ductal carcinoma of breast.
|
Life Sci
|
2008
|
1.03
|
|
16
|
Clinical significance of altered expression of β-catenin and E-cadherin in oral dysplasia and cancer: potential link with ALCAM expression.
|
PLoS One
|
2013
|
1.02
|
|
17
|
Angiogenesis in cutaneous melanoma: pathogenesis and clinical implications.
|
Microsc Res Tech
|
2003
|
1.02
|
|
18
|
Stromelysin 3, Ets-1, and vascular endothelial growth factor expression in oral precancerous and cancerous lesions: correlation with microvessel density, progression, and prognosis.
|
Clin Cancer Res
|
2005
|
1.01
|
|
19
|
Expression of DNA methyltransferases in breast cancer patients and to analyze the effect of natural compounds on DNA methyltransferases and associated proteins.
|
J Breast Cancer
|
2013
|
1.01
|
|
20
|
Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography-tandem mass spectrometry.
|
J Proteome Res
|
2008
|
1.00
|
|
21
|
Stromelysin-2 overexpression in human esophageal squamous cell carcinoma: potential clinical implications.
|
Cancer Detect Prev
|
2002
|
0.99
|
|
22
|
S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia.
|
Int J Cancer
|
2013
|
0.99
|
|
23
|
Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/beta-catenin signaling.
|
Chem Biol Interact
|
2009
|
0.99
|
|
24
|
Detection of RASSF1A and RARbeta hypermethylation in serum DNA from breast cancer patients.
|
Epigenetics
|
2006
|
0.97
|
|
25
|
14-3-3 zeta as novel molecular target for cancer therapy.
|
Expert Opin Ther Targets
|
2012
|
0.96
|
|
26
|
Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients.
|
Cell Oncol
|
2009
|
0.96
|
|
27
|
Stromelysin-3 expression is an early event in human oral tumorigenesis.
|
Int J Cancer
|
2003
|
0.95
|
|
28
|
Small interfering RNA targeting 14-3-3ζ increases efficacy of chemotherapeutic agents in head and neck cancer cells.
|
Mol Cancer Ther
|
2010
|
0.94
|
|
29
|
Alterations of rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma.
|
Oncology
|
2005
|
0.94
|
|
30
|
CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients.
|
Clin Biochem
|
2009
|
0.94
|
|
31
|
Expression of NF-kappaB parallels COX-2 expression in oral precancer and cancer: association with smokeless tobacco.
|
Int J Cancer
|
2007
|
0.93
|
|
32
|
Ets-1 and VEGF expression correlates with tumor angiogenesis, lymph node metastasis, and patient survival in esophageal squamous cell carcinoma.
|
J Cancer Res Clin Oncol
|
2003
|
0.93
|
|
33
|
Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients.
|
Int J Cancer
|
2009
|
0.92
|
|
34
|
Differential expression of G-protein coupled receptor 56 in human esophageal squamous cell carcinoma.
|
Cancer Lett
|
2006
|
0.92
|
|
35
|
Promoter hypermethylation in Indian primary oral squamous cell carcinoma.
|
Int J Cancer
|
2010
|
0.92
|
|
36
|
Prognostic significance of nuclear pSTAT3 in oral cancer.
|
Head Neck
|
2011
|
0.91
|
|
37
|
Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression.
|
Tumour Biol
|
2010
|
0.91
|
|
38
|
Transglutaminase 2 overexpression in tumor stroma identifies invasive ductal carcinomas of breast at high risk of recurrence.
|
PLoS One
|
2013
|
0.90
|
|
39
|
Discovery of deregulation of zinc homeostasis and its associated genes in esophageal squamous cell carcinoma using cDNA microarray.
|
Int J Cancer
|
2007
|
0.90
|
|
40
|
Overexpression of prothymosin alpha predicts poor disease outcome in head and neck cancer.
|
PLoS One
|
2011
|
0.89
|
|
41
|
Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents.
|
Mol Cell Biochem
|
2010
|
0.89
|
|
42
|
Clinical significance of GPR56, transglutaminase 2, and NF-κB in esophageal squamous cell carcinoma.
|
Cancer Invest
|
2010
|
0.89
|
|
43
|
14-3-3 zeta is a molecular target in guggulsterone induced apoptosis in head and neck cancer cells.
|
BMC Cancer
|
2010
|
0.88
|
|
44
|
DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients.
|
Tumour Biol
|
2012
|
0.88
|
|
45
|
An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.
|
PLoS One
|
2012
|
0.88
|
|
46
|
TC21/R-Ras2 upregulation in esophageal tumorigenesis: potential diagnostic implications.
|
Oncology
|
2005
|
0.87
|
|
47
|
Clinical significance of TC21 overexpression in oral cancer.
|
J Oral Pathol Med
|
2009
|
0.87
|
|
48
|
Immunohistochemical analysis based Ep-ICD subcellular localization index (ESLI) is a novel marker for metastatic papillary thyroid microcarcinoma.
|
BMC Cancer
|
2012
|
0.86
|
|
49
|
Significance of promoter hypermethylation of p16 gene for margin assessment in carcinoma tongue.
|
Head Neck
|
2009
|
0.86
|
|
50
|
Clinical significance of sperm protein 17 expression and immunogenicity in esophageal cancer.
|
Int J Cancer
|
2007
|
0.86
|
|
51
|
Guggulsterone (GS) inhibits smokeless tobacco and nicotine-induced NF-κB and STAT3 pathways in head and neck cancer cells.
|
Carcinogenesis
|
2010
|
0.86
|
|
52
|
Establishment and characterization of a cell line from smokeless tobacco associated oral squamous cell carcinoma.
|
Oral Oncol
|
2003
|
0.85
|
|
53
|
Secretome-based identification and characterization of potential biomarkers in thyroid cancer.
|
J Proteome Res
|
2010
|
0.85
|
|
54
|
Clinical significance of Stratifin, ERalpha and PR promoter methylation in tumor and serum DNA in Indian breast cancer patients.
|
Clin Biochem
|
2009
|
0.84
|
|
55
|
MGMT expression in oral precancerous and cancerous lesions: correlation with progression, nodal metastasis and poor prognosis.
|
Oral Oncol
|
2006
|
0.84
|
|
56
|
Clinical significance of promoter hypermethylation of ERβ and RARβ2 in tumor and serum DNA in Indian breast cancer patients.
|
Ann Surg Oncol
|
2012
|
0.84
|
|
57
|
Smokeless tobacco (khaini) extracts modulate gene expression in epithelial cell culture from an oral hyperplasia.
|
Oral Oncol
|
2005
|
0.83
|
|
58
|
Transcriptional gene expression profile of human esophageal squamous cell carcinoma.
|
Genomics
|
2003
|
0.83
|
|
59
|
Differential expression of retinoic acid receptors in normal and malignant esophageal tissues.
|
J Exp Ther Oncol
|
2004
|
0.83
|
|
60
|
Novel molecular targets of smokeless tobacco (khaini) in cell culture from oral hyperplasia.
|
Toxicology
|
2006
|
0.82
|
|
61
|
Expression analysis of maspin in invasive ductal carcinoma of breast and modulation of its expression by curcumin in breast cancer cell lines.
|
Chem Biol Interact
|
2009
|
0.82
|
|
62
|
Sperm protein 17 is a novel marker for predicting cisplatin response in esophageal squamous cancer cell lines.
|
Int J Cancer
|
2010
|
0.81
|
|
63
|
A sensitive test for the detection of specific DSB repair defects in primary cells from breast cancer specimens.
|
Int J Cancer
|
2008
|
0.81
|
|
64
|
siRNA-mediated downregulation of TC21 sensitizes esophageal cancer cells to cisplatin.
|
World J Gastroenterol
|
2012
|
0.80
|
|
65
|
Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer.
|
Oncology
|
2004
|
0.80
|
|
66
|
Soluble and membranous vascular endothelial growth factor receptor-2 in pregnancies complicated by pre-eclampsia.
|
Yonsei Med J
|
2009
|
0.80
|
|
67
|
Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
|
Mass Spectrom Rev
|
2010
|
0.79
|
|
68
|
Loss of DLC1 is an independent prognostic factor in patients with oral squamous cell carcinoma.
|
Mod Pathol
|
2011
|
0.79
|
|
69
|
Guggulsterone targets smokeless tobacco induced PI3K/Akt pathway in head and neck cancer cells.
|
PLoS One
|
2011
|
0.79
|
|
70
|
Secretome proteins as candidate biomarkers for aggressive thyroid carcinomas.
|
Proteomics
|
2013
|
0.79
|
|
71
|
Biotinidase is a novel marker for papillary thyroid cancer aggressiveness.
|
PLoS One
|
2012
|
0.79
|
|
72
|
Clinical significance of phosphatidyl inositol synthase overexpression in oral cancer.
|
BMC Cancer
|
2010
|
0.79
|
|
73
|
Retinoic acid receptor-alpha as a prognostic indicator in oral squamous cell carcinoma.
|
Int J Cancer
|
2003
|
0.78
|
|
74
|
Mitogen activated protein kinase kinase kinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis.
|
BMC Cancer
|
2014
|
0.78
|
|
75
|
Activated leukocyte cell adhesion molecule is a marker for thyroid carcinoma aggressiveness and disease-free survival.
|
Thyroid
|
2013
|
0.77
|
|
76
|
Overexpression of a splice variant of oncostatin M receptor beta in human esophageal squamous carcinoma.
|
Cell Oncol (Dordr)
|
2011
|
0.77
|
|
77
|
Clinical significance of promoter hypermethylation of RASSF1A, RARbeta2, BRCA1 and HOXA5 in breast cancers of Indian patients.
|
Life Sci
|
2008
|
0.77
|
|
78
|
Clinical significance of mannose-binding lectin-associated serine protease-2 expression in esophageal squamous cell carcinoma.
|
Int J Cancer
|
2006
|
0.76
|
|
79
|
Nuclear Ep-ICD accumulation predicts aggressive clinical course in early stage breast cancer patients.
|
BMC Cancer
|
2014
|
0.76
|
|
80
|
Effect of polymorphisms in XRCC1, CCND1 and GSTM1 and tobacco exposure as risk modifier for oral leukoplakia.
|
Int J Biol Markers
|
2009
|
0.76
|
|
81
|
Establishment and characterisation of two novel breast cancer cell lines.
|
Cell Biol Int
|
2007
|
0.75
|
|
82
|
Differential expression of beta mannosidase in human esophageal cancer.
|
Int J Cancer
|
2004
|
0.75
|
|
83
|
How will increasing our knowledge of the head and neck cancer cells' secretome benefit head and neck squamous cell carcinoma patients?
|
Expert Rev Proteomics
|
2012
|
0.75
|